Helix BioPharma (TSE:HBP) Posts Earnings Results

Helix BioPharma (TSE:HBP) issued its quarterly earnings data on Friday. The biopharmaceutical company reported C($0.01) earnings per share for the quarter, FiscalAI reports.

Helix BioPharma Stock Performance

TSE HBP opened at C$1.58 on Friday. The company has a debt-to-equity ratio of 2.34, a current ratio of 0.04 and a quick ratio of 1.04. Helix BioPharma has a 1-year low of C$0.84 and a 1-year high of C$5.40. The business has a 50 day simple moving average of C$1.74 and a two-hundred day simple moving average of C$1.96. The stock has a market capitalization of C$120.68 million, a PE ratio of -26.33 and a beta of 0.42.

Helix BioPharma Company Profile

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.